Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 1210 www.fsem.ac.uk | Excellence in Musculoskeletal Medicine, Exercise Medicine and Team Care FSEM - PROFESSIONAL CODE 4.8.  Maintain the patient’s confidentiality when requested to do so. This may bring the Member or Fellow in breach of his/her employment contractual obligations and employer expectations. In the first instance discuss with the patient your dilemma, if there is strong public interest or legal grounds for breaching that confidentiality explain to the patient your reasoning for breaching his/her confidentiality. If in doubt seek guidance form your medical indemnity provider. 4.9.  Be aware of the national and international current regulations on anti-doping in sport. You should not assist, support or ignore practices, policies or procedures that enhance athletic performance and contravene the national or international doping regulations. 4.10.  Report practices, policies or procedures that contravene national and international anti-doping regulations. There are facilities to do this in an anonymised manner. 4.11.  Discuss with your indemnity provider your management of a patient who wishes to cease using a prohibited substance for the purpose of performance enhancement and is seeking your assistance in using an alternative, non-prohibited substance(s). 4.12.  Make it clear to your patient if you are receiving sponsorship, products or support which may in any way affect the optimal health options for your patient. 4.13.  Make it clear to your patient if you receive financial gain or benefit in kind from the use of products, drugs or equipment in the course of his/her treatment. 4.14.  Be extremely cautious about giving personal endorsement to methods, products or equipment which do not have a robust peer reviewed evidence base. 4.15.  Inform the patient if a novel treatment is being proposed, particularly any known or potential short, middle or long term side effects. Where there is a lack of evidence in support of a novel treatment this should be communicated to the patient. You should: 4.16.  Discuss with patients the challenges obtaining consent in high pressure situations and try where possible to prepare for this in advance with the team and support staff. Where you feel the patient cannot give suitably informed consent remove him/her from the environment in order to do so. 4.17.  Wherever possible educate patients, coaches and management agencies about the negative health effects of performance enhancing methods and drugs. 4.18.  Declare any relationship with third parties which may influence the content of your presentation at conferences or scientific meetings.